Journal of the National Cancer Institute

Journal

Publication Venue For

  • A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction among Childhood Cancer Survivors.  114:1109-1116. 2022
  • Policies and Practices to Address Cancer's Long-Term Adverse Consequences.  114:1065-1071. 2022
  • Rural–Urban Disparities in Cancer Outcomes: Opportunities for Future Research.  114:940-952. 2022
  • Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.  114:571-578. 2022
  • The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer.  113:1570-1580. 2021
  • Progression of Frailty in Survivors of Childhood Cancer: A St. Jude Lifetime Cohort Report.  113:1415-1421. 2021
  • Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.  113:1369-1378. 2021
  • Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+T-Cell Exhaustion.  113:1036-1043. 2021
  • Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC cardio-oncology and imaging councils.  113:513-522. 2021
  • Poverty and Survival in Childhood Cancer: A Framework to Move Toward Systemic Change.  113:227-230. 2021
  • Strategies to Prevent or Remediate Cancer and Treatment-Related Aging.  113:112-122. 2021
  • The pros and cons of incorporating transcriptomics in the age of precision oncology.  111:1016-1022. 2019
  • Too Early to Worry About Blueberries.  111:103-104. 2019
  • A high-risk haplotype for premature menopause in childhood cancer survivors exposed to gonadotoxic therapy.  110:895-904. 2018
  • Response.  110:433-434. 2018
  • Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer after Childhood Cancer.  109. 2017
  • Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.  109. 2017
  • Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.  108. 2016
  • A Candidate-Pathway Approach to Identify Gene-Environment Interactions: Analyses of Colon Cancer Risk and Survival.  107. 2015
  • Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer.  107. 2015
  • Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination.  106. 2014
  • Impact of treatment site in adolescents and young adults with central nervous system tumors.  106. 2014
  • Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.  106. 2014
  • Re: Tumor Boards and the Quality of Cancer Care.  105:1839-1839. 2013
  • Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.  105:1221-1229. 2013
  • Fruit and vegetable intake and risk of breast cancer by hormone receptor status.  105:219-236. 2013
  • Leveraging epidemiology and clinical studies of cancer outcomes: Recommendations and opportunities for translational research.  105:85-94. 2013
  • Flexible sigmoidoscopy in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial: Added yield from a second screening examination.  104:280-289. 2012
  • Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up.  104:125-132. 2012
  • YB-1, the E2F pathway, and regulation of tumor cell growth.  104:133-146. 2012
  • Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial.  102:1835-1844. 2010
  • Baseline Characteristics of Participants in the Randomized National Lung Screening Trial.  102:1771-1779. 2010
  • Lung cancer screening in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.  102:722-731. 2010
  • Iace and colorectal cancer disparities: Health-care utilization vs different cancer susceptibilities.  102:538-546. 2010
  • Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.  102:325-339. 2010
  • Variability of interpretive accuracy among diagnostic mammography facilities.  101:814-827. 2009
  • Multi-institutional validation of the predictive value of ki-67 labeling index in patients with urinary bladder cancer.  101:114-119. 2009
  • Calcium plus vitamin D supplementation and the risk of breast cancer.  100:1581-1591. 2008
  • Mammography facility characteristics associated with interpretive accuracy of screening mammography.  100:876-887. 2008
  • Serum vitamin D concentration and prostate cancer risk: A nested case-control study.  100:796-804. 2008
  • Low-fat dietary pattern and cancer incidence in the women's health initiative dietary modification randomized controlled trial.  99:1534-1543. 2007
  • Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.  99:309-321. 2007
  • Statin use and breast cancer: Prospective results from the women's health initiative.  98:700-707. 2006
  • Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's health initiative randomized trial.  97:1366-1376. 2005
  • Physician predictors of mammographic accuracy.  97:358-367. 2005
  • Accuracy of screening mammography interpretation by characteristics of radiologists.  96:1840-1850. 2004
  • A new member of the growing family of metastasis suppressors identified in prostate cancer.  95:839-841. 2003
  • Detection of ductal carcinoma in situ in women undergoing screening mammography.  94:1546-1554. 2002
  • Performance of diagnostic mammography for women with signs or symptoms of breast cancer.  94:1151-1159. 2002
  • In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.  94:741-749. 2002
  • Metastasis-suppressor genes: A review and perspective on an emerging field.  92:1717-1730. 2000
  • What defines a useful marker of metastasis in human cancer?.  91:1351-1353. 1999
  • Re: loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer..  89:585-586. 1997
  • KiSS-1, a novel human malignant melanoma metastasis-suppressor gene.  88:1731-1737. 1996
  • Expression of p160erbb-3 and p185erbb-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.  86:1140-1145. 1994
  • Body dimension differences in men with or without prostate cancer.  84:1363-1364. 1992
  • Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential.  84:165-174. 1992
  • The role of soy products in reducing risk of cancer.  83:541-546. 1991
  • Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.  80:932-936. 1988
  • Phase I trial of multiple large doses of murine monoclonal antibody Co17-1A. II. Pharmacokinetics and immune response.  80:937-942. 1988
  • Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veterans administration cooperative study no. 188.  80:90-97. 1988
  • Monoclonal IgM antibodies that inhibit primary Moloney murine sarcoma growth.  78:547-556. 1987
  • Biologic properties of cell lines derived from canine mammary carcinomas.  77:783-792. 1986
  • Direct relationship between high-energy phosphate content and blood flow in thermally treated murine tumors.  75:885-889. 1985
  • Inhibition of macrophage-mediated tumor cell destruction by oxidized lipoproteins.  73:469-474. 1984
  • Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis.  71:455-461. 1983
  • Genetic epidemiology of breast cancer and associated cancers in high-risk families. II. Linkage analysis.  71:463-467. 1983
  • Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma.  68:507-517. 1982
  • Retinoic acid: Enhancement of a tumor and inhibition of interferon’s antitumor action.  67:95-97. 1981
  • Vitamin A-induced density-dependent inhibition of L-cell proliferation..  58:795-801. 1977
  • Brief communication: Vitamin a-induced density-dependent inhibition of l-cell proliferation.  58:795-801. 1977
  • Effect of dibutyryl cyclic adenosine 5' monophosphate on protein synthesis in L5178Y cells after hyperthermia.  59:1469-1473. 1977
  • Monitoring of Murine Osteosarcoma by Serial Alkaline Phosphatase Determinations.  57:837-839. 1976
  • Quantitation of total body tumor cells (MOPC 104E). I. Subcutaneous tumor model.  52:1199-1202. 1974
  • Quantitation of total-body tumor cells (MOPC 104E). II. Ascites tumor model.  53:767-771. 1974
  • International Standard Serial Number (issn)

  • 0027-8874
  • Electronic International Standard Serial Number (eissn)

  • 1460-2105